Interview: Jung Hyun Ho – Founder & CEO, Medytox – Korea
Medytox is the most valuable pharmaceutical business in Korea, with a highly successful botulinum toxin product on the market, and can only grow further when they finish development of their…
Medytox has successfully developed the fourth botulinum toxin type A product in the world, and today exports products to more than 60 countries including Japan, Thailand, India, and Brazil. Medytox has been making efforts to penetrate into the US and European market in the near future to show its presence as a leading global biopharmaceutical company.
Medytox is at the forefront of the Korean biopharmaceutical industry, thanks to its excellent R&D capabilities with top-teir biotechnologists, and to its state-of-the-art operations and production facilties. Moreover, Medytox is going to become a frontier in the field of biopharmaceuticals due to its passion and courage to embrace global challenges.
Contact Details
78, Gangni 1-gil, Ochang-eup, Cheongwon-gu,
Cheongju-si, Chungcheongbuk-do
Korea
Medytox is the most valuable pharmaceutical business in Korea, with a highly successful botulinum toxin product on the market, and can only grow further when they finish development of their…
The Korean Institute of Toxicology (KIT) is a government-funded research institute that evaluates the safety of medicine, bio-related products and chemicals. PharmaBoardroom talks to Lee Sang-Joon, President of KIT about…
Korea possesses enormous potential to become an exporter of futuristic health systems in the near future, and has already started the process. Kim Han-Joong, chairman of the strategy committee at…
The Korea Drug Research Association (KDRA) was founded in 1986 to represent local pharmaceutical companies in their mission for global drug development. Kang-Choo Lee, president of KDRA, discusses the current…
The president of Astellas Korea offers his perspectives on Korea as a base for primary and clinical research, and the company’s recent partnerships in the country. You became president…
The head researcher at P&K Skin Research Center discusses the potential of South Korea as a clinical trial hub, and the company’s current expansion plans. What differentiates P&K Skin…
Don Hyun, president of MSD Korea, shares his vision to bring Korean pharmaceutical companies to the global stage and to bring a locally produced drug to blockbuster status in the…
The director of the Hanyang University Hospital for Rheumatic Diseases (HUHRD), discusses Korea’s leading role in developing biosimilars as well as the hospital’s efforts to curb chronic diseases. As…
The Korea National Enterprise for Clinical Trials (KoNECT) was established in 2007 by the Korean government to meet the increasing demand for local clinical trials and strengthen the country’s clinical research…
The director general of Korea’s Bureau of Health Industry explains what has led to Korea’s excellent healthcare system, and the competitiveness of the country’s pharmaceutical sector. Can you provide our…
Jung Kee-Taig, president of the Korea Health Industry Development Institute (KHIDI), outlines his “Health Economy 2030” for Korea, and highlights the institute’s domestic and international collaborations. KHIDI aims to…
Prior to founding Bioneer, Park Han-Oh spent a number of years working at KRIBB. Today he speaks about the company’s latest breakthrough technology in DNA synthesis and his outlook for…
Oh Pil-Soo, managing director of Lundbeck Korea, talks about the challenges of pricing and reimbursement in the CNS area and remaining committed to Korea in terms of clinical research. …
See our Cookie Privacy Policy Here
